AU2001277561A1 - Biphenyl derivatives and the use thereof as integrin inhibitors - Google Patents

Biphenyl derivatives and the use thereof as integrin inhibitors

Info

Publication number
AU2001277561A1
AU2001277561A1 AU2001277561A AU7756101A AU2001277561A1 AU 2001277561 A1 AU2001277561 A1 AU 2001277561A1 AU 2001277561 A AU2001277561 A AU 2001277561A AU 7756101 A AU7756101 A AU 7756101A AU 2001277561 A1 AU2001277561 A1 AU 2001277561A1
Authority
AU
Australia
Prior art keywords
biphenyl derivatives
integrin inhibitors
integrin
inhibitors
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001277561A
Inventor
Simon Goodman
Gunter Holzemann
Wolfgang Stahle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2001277561A1 publication Critical patent/AU2001277561A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001277561A 2000-08-23 2001-08-02 Biphenyl derivatives and the use thereof as integrin inhibitors Abandoned AU2001277561A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10041423 2000-08-23
DE10041423A DE10041423A1 (en) 2000-08-23 2000-08-23 biphenyl
PCT/EP2001/008970 WO2002016328A1 (en) 2000-08-23 2001-08-02 Biphenyl derivatives and the use thereof as integrin inhibitors

Publications (1)

Publication Number Publication Date
AU2001277561A1 true AU2001277561A1 (en) 2002-03-04

Family

ID=7653540

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001277561A Abandoned AU2001277561A1 (en) 2000-08-23 2001-08-02 Biphenyl derivatives and the use thereof as integrin inhibitors

Country Status (17)

Country Link
US (1) US20040010023A1 (en)
EP (1) EP1311489A1 (en)
JP (1) JP2004524264A (en)
KR (1) KR20030022418A (en)
CN (1) CN1447799A (en)
AU (1) AU2001277561A1 (en)
BR (1) BR0113374A (en)
CA (1) CA2420208A1 (en)
CZ (1) CZ2003671A3 (en)
DE (1) DE10041423A1 (en)
HU (1) HUP0301784A3 (en)
MX (1) MXPA03001557A (en)
NO (1) NO20030813D0 (en)
PL (1) PL359668A1 (en)
SK (1) SK2962003A3 (en)
WO (1) WO2002016328A1 (en)
ZA (1) ZA200302256B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112771A1 (en) 2001-03-16 2002-09-26 Merck Patent Gmbh New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections
DE10127041A1 (en) * 2001-06-02 2002-12-05 Merck Patent Gmbh New glycine N-(1-biphenyl-4-yl-2-substituted-ethyl)-amides, are integrin receptor inhibitors useful for treating e.g. angiogenic, cardiovascular, inflammatory and osteolytic or tumor diseases
CN1964740A (en) 2004-04-02 2007-05-16 加利福尼亚大学董事会 Methods and compositions for treating and preventing diseases associated with alphaVbeta5 integrin
BR112012001463A2 (en) 2009-07-24 2016-03-15 Univ California methods and compositions for treating and preventing alpha5-integrin-associated disease5
RU2769702C2 (en) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Avb6 integrin inhibitors
MA47692A (en) 2017-02-28 2020-01-08 Morphic Therapeutic Inc INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
WO2019200202A1 (en) 2018-04-12 2019-10-17 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
MX2021002181A (en) 2018-08-29 2021-07-15 Morphic Therapeutic Inc Inhibiting î±v î²6 integrin.
CA3154269A1 (en) 2019-10-16 2021-04-22 Matthew G. Bursavich Inhibiting human integrin .alpha.4.beta.7

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0880511A4 (en) * 1996-01-16 1999-06-16 Merck & Co Inc Integrin receptor antagonists
AU751950B2 (en) * 1997-11-24 2002-09-05 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
CN1146541C (en) * 1999-02-20 2004-04-21 默克专利股份有限公司 Beta-alanine derivatives

Also Published As

Publication number Publication date
CN1447799A (en) 2003-10-08
ZA200302256B (en) 2004-07-26
DE10041423A1 (en) 2002-03-07
US20040010023A1 (en) 2004-01-15
MXPA03001557A (en) 2003-06-06
NO20030813L (en) 2003-02-21
CA2420208A1 (en) 2003-02-21
EP1311489A1 (en) 2003-05-21
PL359668A1 (en) 2004-08-23
HUP0301784A2 (en) 2003-12-29
NO20030813D0 (en) 2003-02-21
SK2962003A3 (en) 2003-06-03
CZ2003671A3 (en) 2003-06-18
KR20030022418A (en) 2003-03-15
JP2004524264A (en) 2004-08-12
WO2002016328A1 (en) 2002-02-28
BR0113374A (en) 2003-07-08
HUP0301784A3 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
AU2001287299A1 (en) Benzoylpyrazols and their use as herbicides
AU2001256184A1 (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
AU2002226486A1 (en) Novel c-glycoside derivatives and use thereof
AU2001262089A1 (en) Alpha4beta1 and alpha4beta7 integrin inhibitors
AU2002226487A1 (en) Novel c-glycoside derivatives and use thereof
AU2001277526A1 (en) Substituted benzo-nitro-heterocycles and use thereof as herbicides
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2002219135A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors
HUP0203961A3 (en) 3-phenoxy-1-phenyl acetylene derivatives and their use as herbicedes
AU2001240637A1 (en) Novel imidazotriazinones and the use thereof
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors
AU2001277561A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
AU2001261750A1 (en) Laminate and its use
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU2001266124A1 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU2000231564A1 (en) Phosphororganic compounds and the use thereof
AU4432001A (en) Trityl-type compounds and their use
AU2001235364A1 (en) Tetrahydronaphtalene derivatives and their use
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU8973201A (en) Biphenyl derivatives and the use thereof as integrin inhibitors
AU2001289732A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
AU2001234180A1 (en) Benzamide derivative and use thereof
AU2001246897A1 (en) Acetylene derivatives and herbicides containing the same
AU2001282268A1 (en) Phenantridine derivatives and their use as anti-telomerase agent
AU6286101A (en) New use